Aigen Investment Management, LP Fibrogen Inc Transaction History

Aigen Investment Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$2.49 - $20.59 $234,413 - $1.94 Million	94,142 New	94,142 $254,000
Q4 2021 Feb 11, 2022	SELL	$9.93 - $15.39 $344,670 - $534,186	-34,710 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$10.18 - $26.64 $353,347 - $924,674	34,710 New	34,710 $355,000
Q4 2020 Feb 12, 2021	SELL	$37.09 - $48.97 $213,749 - $282,214	-5,763 Closed	0 $0
Q3 2020 Nov 06, 2020	SELL	$40.47 - $45.5 $132,782 - $149,285	-3,281 Reduced 36.28%	5,763 $237,000
Q2 2020 Aug 10, 2020	BUY	$32.57 - $42.83 $294,563 - $387,354	9,044 New	9,044 $367,000
Q1 2020 May 08, 2020	SELL	$23.3 - $45.96 $52,378 - $103,318	-2,248 Closed	0 $0
Q4 2019 Feb 04, 2020	BUY	$34.58 - $48.06 $77,735 - $108,038	2,248 New	2,248 $96,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Aigen Investment Management, LP, based on Form 13F filings with the SEC.

Stay updated on Aigen Investment Management, LP with notifications on news.